Improvement of wasting by treatment with a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, MRA in multicentric Castleman's disease. A phase II clinical trial of 28 patients.

被引：0
|
作者：
Nishimoto, N [1 ]
Kanakura, Y [1 ]
Aozasa, K [1 ]
Johkoh, T [1 ]
Nakano, N [1 ]
Nakamura, M [1 ]
Ikeda, Y [1 ]
Sasaki, T [1 ]
Nishioka, K [1 ]
Hara, M [1 ]
Taguchi, H [1 ]
Kimura, Y [1 ]
Kato, Y [1 ]
Kishimoto, T [1 ]
Yoshizaki, K [1 ]
机构：
[1] Osaka Univ, Sch Hlth & Sport Sci, Dept Med Sci 1, Osaka, Japan
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
760
引用
下载
收藏
页码：202A / 203A
页数：2
相关论文
共 43 条
  • [31] Recruitment in a randomized, double-blind, placebo-controlled study to assess siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in patients with multicentric Castleman's disease.
    Van Rhee, Frits
    Capra, Marcelo
    Wong, Raymond
    Vermeulen, Jessica
    Safer, Karim
    Todorovic, Marija
    Rhoten, Patricia
    Van de Velde, Helgi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study
    Nishimoto, N
    Yoshizaki, K
    Maeda, K
    Kuritani, T
    Deguchi, H
    Sato, B
    Imai, N
    Suemura, M
    Kakehi, T
    Takagi, N
    Kishimoto, T
    JOURNAL OF RHEUMATOLOGY, 2003, 30 (07) : 1426 - 1435
  • [33] Blocking interleukin-6 (IL-6) by tocilizumab (A humanized anti-interleukin-6 receptor monoclonal antibody) monotherapy reduces joint damage in active rheumatoid arthritis (RA): Evidence from a X-ray reader-blinded randomised controlled trial.
    Nishimoto, N
    Hashimoto, J
    Miyasaka, N
    Yamamoto, K
    Kawai, S
    Takeuchi, T
    Murata, N
    van der Heijde, D
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 4109 - 4109
  • [34] Long-Term Safety in a Phase 1 Study of Siltuximab (CNTO 328), an Anti-Interleukin-6 Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
    Kurzrock, Razelle
    Voorhees, Peter M.
    Casper, Corey
    Furman, Richard R.
    Fayad, Luis
    Lonial, Sagar
    Borghaei, Hossein
    Jagannath, Sundar
    Sokol, Lubomir
    Usmani, Saad
    van de Velde, Helgi
    Qin, Xiang
    Qi, Ming
    Cornfeld, Mark J.
    van Rhee, Frits
    BLOOD, 2011, 118 (21) : 1693 - 1693
  • [35] INFLAMMATORY AND ANEMIA-RELATED MARKERS IN A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SILTUXIMAB (ANTI-IL-6 MONOCLONAL ANTIBODY) IN MULTICENTRIC CASTLEMAN'S DISEASE PATIENTS
    Casper, C.
    Chaturvedi, S.
    Munshi, N.
    Wong, R.
    Qi, M.
    Schaffer, M.
    Bandekar, R.
    Huang, Y.
    Hall, B.
    Vermeulen, J.
    Reddy, M.
    Van Rhee, F.
    HAEMATOLOGICA, 2014, 99 : 465 - 465
  • [36] Population Pharmacokinetic and Pharmacodynamic Modeling of an Anti-Interleukin-6 Chimeric Monoclonal Antibody, Siltuximab (CNTO 328), in Patients with B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
    Xie, Lanyi
    Li, Lilian Y.
    Kurzrock, Razelle
    van Rhee, Frits
    Qin, Xiang
    Reddy, Manjula
    Qi, Ming
    Davis, Hugh M.
    Zhou, Honghui
    Puchalski, Thomas A.
    BLOOD, 2012, 120 (21)
  • [37] CNTO 328, an anti-interleukin (IL)-6 monoclonal antibody (mAb) - Preliminary results of subjects with Castleman's disease from a phase 1 study in selected hematological malignancies.
    VanRhee, Frits
    Fayad, Luis
    Borghaei, Hossein
    Voorhees, Peter M.
    Orlowski, Robert Z.
    Furman, Richard R.
    Zaki, Mohamed
    Prabhakar, Uma
    Jiao, Trina
    Lihou, Christine
    Garay, Carlos A.
    Kurzrock, Razelle
    BLOOD, 2006, 108 (11) : 771A - 772A
  • [38] A Phase I Study of CNTO 328, An Anti-Interelukin-6 Monoclonal Antibody in Patients with A-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease.
    Kurzrock, Razelle
    Fayad, Luis
    Voorhees, Peter
    Furman, Richard R.
    Lonial, Sagar
    Borghaei, Hossein
    Jagannath, Sundar
    Sokol, Lubomir
    Cornfeld, Mark
    Qi, Ming
    Jiao, Trina
    Herring, Jennifer
    Qin, Xiang
    van Rhee, Frits
    BLOOD, 2008, 112 (11) : 371 - 372
  • [39] SWOG S0354: A phase II trial of CNTO328, a monoclonal antibody against interleukin-6 (IL-6), in chemotherapy pretreated patients (pts) with castration- resistant prostate cancer (CRPC)
    Pinski, J. K.
    Goldman, B.
    Dorff, T.
    Mack, P.
    Lara, P., Jr.
    van Veldhuizen, P.
    Quinn, D.
    Hussain, M. H.
    Thompson, I. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
    Karpouzas, George
    Takeuchi, Tsutomu
    Thorne, Carter
    Sheng, Shihong
    Li, Xiaoming
    Rao, Ravi
    Fei, Kaiyin
    Hsu, Benjamin
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
12345